Abstract:IL-1β is an essential cytokine, but its release needs to be strictly controlled to avoid severe inflammatory manifestations. Lacking a signal sequence, IL-1β does not follow the endoplasmic reticulum-Golgi route. Several pathways have been proposed to mediate its release. One involves the translocation of pro-IL-1β into intracellular vesicles of lysosomal origin that eventually fuse with the plasma membrane. Another exploits pores formed on the plasma membrane upon proteolytic cleavage of gasdermin D (GSDMD). Here we investigated how primary monocytes—the main source of IL-1β in humans—control IL-1β release in response to pro-inflammatory stimuli of increasing intensity and found that two different routes are induced depending on the strength of activation. Triggering of Toll-like receptor 4 (TLR4) by LPS induces slow IL-1β release through LAMP2A+ vesicles. In contrast, the simultaneous stimulation of TLR2, TLR4 and TLR7/8 drives high levels of ROS, GSDMD cleavage and faster IL-1β secretion. Drugs blocking ROS production prevent GSDMD cleavage supporting a role of oxidative stress in GSDMD-mediated secretion. Singly stimulated monocytes undergo apoptosis, whereas triple stimulation triggers pyroptosis, which might amplify inflammation. In both cases, however, IL-1β secretion precedes cell death. Inhibition of caspases 4/5 prevents GSDMD cleavage and pore-mediated secretion, but not vesicular release. The two pathways also display other distinct pharmacologic sensitivities that reflect the underlying mechanisms. Remarkably, single TLR4 stimulation is sufficient to activate massive, GSDMD-mediated IL-1β secretion in monocytes from patients affected by Cryopyrin Associated Periodic Syndrome (CAPS), an autoinflammatory disease linked to NLRP3 mutations. The exaggerated sensitivity to activation correlates with high basal ROS levels in CAPS monocytes. In conclusion, the vesicular pathway limits IL-1β release upon low pathogen load while stronger stimulation or concomitant cell stress induce instead uncontrolled secretion via GSDMD leading to detrimental inflammatory manifestations.

IL-1 family cytokines serve as 'activity recognition receptors' for aberrant protease activity indicative of danger

Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis.

The tetrapeptide sequence of IL-1β regulates its recruitment and activation by inflammatory caspases

Activation and Pharmacological Regulation of Inflammasomes

[Inflammasome and interleukin 1]

The three cytokines IL-1β, IL-18, and IL-1α share related but distinct secretory routes

An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells

The Dual Functions of IL-1 Receptor-Associated Kinase 2 in TLR9-Mediated IFN and Proinflammatory Cytokine Production

Molecular aspects of Interleukin-36 cytokine activation and regulation

Progressive waves of IL-1β release by primary human monocytes via sequential activation of vesicular and gasdermin D-mediated secretory pathways

Gasdermin D pore structure reveals preferential release of mature interleukin-1

How Inflammasomes Inform Adaptive Immunity

Lysosomal cathepsins act in concert with Gasdermin-D during NAIP/NLRC4-dependent IL-1β secretion

Sensing damage by the NLRP3 inflammasome

Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor

Cryopyrin activates the inflammasome in response to toxins and ATP

Inflammatory caspases are innate immune receptors for intracellular LPS

Structural Insights into the Assembly and Activation of IL-1β with Its Receptors

Structural insights into the assembly and activation of IL-1[beta] with its receptors

IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction

Cutting edge: Cytosolic bacterial DNA activates the inflammasome via Aim2